IRBM, which is cooperating with AstraZeneca in developing a vaccine against COVID-19, could be listed on the stock exchange, as reported in London South East.
Piero Di Lorenzo, CEO of the Italian biotechnology firm, told the newspaper Il Riformista that "many big companies would like to enter our capital. We are receiving interest from all over the world and I don't rule out any option."
However, he indicated that such a decision was not currently a priority, given the focus on the vaccine.
Earlier this month, IRBM said Italy could have its first doses of the vaccine by the end of November.
According to the news source, the group has already produced tens of thousands of vaccine doses for the trial stage and has the potential to produce up to 10 million doses a year.
However, it does not have a production contract with AstraZeneca yet, "but it is likely to, in the future," Di Lorenzo said.
To read more NewsPoints articles, click here.